JeremySladeAbramsonMD

Oncology • Boston, MA

Hematologic Oncology

Center for Lymphoma, Massachusetts General Hospital Cancer Center

Join to view full profile

Dr. Abramson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abramson's full profile

Already have an account?

Office
55 Fruit St
# Mgh
Boston, MA 02114
Phone+1 617-724-4000

Fax+1 617-643-1915

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Icahn School of Medicine at Mount SinaiClass of 2000

Certifications & Licensure

MA State Medical License 2002 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry

Clinical Trials

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Start of enrollment: 2008 Jun 01
Completed
Phase 1, Phase 2
Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma Start of enrollment: 2008 Sep 01
Terminated
Phase 2
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas Start of enrollment: 2009 Jul 01
Completed
Phase 2
Bortezomib Plus Rituximab for EBV+ PTLD Start of enrollment: 2011 Nov 01
Completed
Phase 2
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma Start of enrollment: 2010 Dec 01
Completed
Phase 2
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL Start of enrollment: 2012 Dec 01
Completed
Phase 1
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Start of enrollment: 2012 Mar 01
Completed
Phase 2
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2013 Jul 01
Terminated
Early Phase 1
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Start of enrollment: 2013 Sep 05
Completed
Phase 1
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL Start of enrollment: 2014 Oct 01
Completed
Phase 1
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2014 Oct 01
Active, not recruiting
Phase 2
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma Start of enrollment: 2015 Aug 07
Completed
Phase 2
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2015 Dec 01
Active, not recruiting
Phase 1
Pembrolizumab in Neoplasms or Lymphomas Start of enrollment: 2017 Dec 07
Suspended
Phase 2
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL Start of enrollment: 2021 Jun 04
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis.
Leon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy S Abramson, Maria Martinez-Lage
American Journal of Hematology. 2024-12-01
Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma.
Jeremy S Abramson, Robert Stuver, Alex Herrera, Emily Patterson, Yi-Ping Wen
Critical Reviews in Oncology/hematology. 2024-12-01
1 citations
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, random...
Jeremy S Abramson, Matthew Ku, Mark Hertzberg, Hui-Qiang Huang, Christopher P Fox
Lancet. 2024-11-16

Abstracts/Posters

High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements o...
Jeremy S. Abramson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial re...
2019 ASCO Annual Meeting - 6/1/2019
Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene mara...
2019 ASCO Annual Meeting - 6/1/2019
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

$Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL$
Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCLDecember 6th, 2024
Transplant vs. CAR T in DLBCL: Not Always an Either/Or QuestionOctober 21st, 2022
Less Is More: Rituximab Retreatment Tops Maintenance for Follicular LymphomaDecember 16th, 2021
Join now to see all